SCHEMBL15420692

SCHEMBL15420692

CCS(=O)(=O)N[C@H]1CCOC[C@@H]1COc1ccc(-n2cc(Cl)cn2)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP46A1 Q9Y6A2 3/20 0.33
TRPV4 Q9HBA0 3/20 0.33
MELK Q14680 1/20 0.33
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
MAPK10 P53779 1/20 0.32
KCNH2 Q12809 3/20 0.32
GPR119 Q8TDV5 2/20 0.32
MOGAT2 Q3SYC2 1/20 0.32
SCN9A Q15858 2/20 0.32
CHRM1 P11229 1/20 0.31
BRAF P15056 2/20 0.31
KAT5 Q92993 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2B Q13224 1/20 0.31
SCN1A P35498 1/20 0.31
SCN5A Q14524 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12990033 1.00 CYP46A1 (0.33) CYP46A1TRPV4MELKMAPK8MAPK9
SCHEMBL15420015 0.93 CYP46A1 (0.35) CYP46A1TRPV4MELKMAPK8MAPK9
SCHEMBL15420551 0.93 CYP46A1 (0.33) CYP46A1TRPV4MELKMAPK8MAPK9
SCHEMBL15420330 0.92 SCN9A (0.38) CYP46A1MAPK8MAPK9MAPK10SCN9A
SCHEMBL15441821 0.92 SCN9A (0.38) CYP46A1MAPK8MAPK9MAPK10SCN9A
SCHEMBL15440891 0.91 HCRTR2 (0.36) MELKMAPK8MAPK9MAPK10KCNH2
SCHEMBL15420173 0.91 HCRTR2 (0.36) MELKMAPK8MAPK9MAPK10KCNH2
SCHEMBL15440879 0.91 HCRTR2 (0.36) MELKMAPK8MAPK9MAPK10KCNH2
SCHEMBL12989035 0.88 SCN9A (0.34) CYP46A1MELKMAPK8MAPK9MAPK10
SCHEMBL15420165 0.87 CHRM1 (0.34) CYP46A1MELKCHRM1KAT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 CYP46A1 1863/4885TRPV4 2130/4885MELK 2394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.